timothy sykes logo
InMed Pharmaceuticals Experiences Market Shifts Amidst Unstable Global Economy Thumbnail
G Google News

InMed Pharmaceuticals Experiences Market Shifts Amidst Unstable Global Economy

ELLIS HOBBS•UPDATED NOV. 18, 2025, 11:34 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

InMed Pharmaceuticals Inc. stocks have been trading down by -9.09 percent due to increased investor uncertainty and market volatility.

Key Takeaways

  • Recent reports suggest that InMed’s recent financial performance has faced challenges due to global economic instability impacting biotechnology investments.

  • Key investors exhibit cautious optimism, focusing on InMed’s ongoing research advancements, despite an overall slowdown.

  • The biotech industry sees fluctuating stock movements as companies like InMed adapt to evolving market conditions and regulatory pressures.

  • InMed’s financial growth pattern faces scrutiny as analysts weigh the company’s strategic efforts against financial hurdles.

Candlestick Chart

Live Update At 11:33:47 EST: On Tuesday, November 18, 2025 InMed Pharmaceuticals Inc. stock [NASDAQ: INM] is trending down by -9.09%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

InMed Pharmaceuticals, trading under the ticker INM, recently faced a turbulent period marked by notable shifts in stock prices. Their latest earnings report reveals revenues of approximately $4.9M, a pivotal figure in coherence with market expectations.

Despite a grim pretax profit margin standing at -401.7%, the company’s gross margin of 33.7% offers a glimpse of profitability potential. Analysts have raised questions on the impact of a net income from continued operations noted at -$1.72M, highlighting issues in curbing operational costs. The company’s current ratio stands strong at 7, showcasing its robust short-term financial health. However, challenges remain with a ROE of -82.17, pointing towards areas requiring strategic restructures.

More Breaking News

Changing Industry Dynamics

Challenges and Strategy

In a sector witnessing rapid shifts, InMed keenly navigates complex challenges. The company’s profitability has seen setbacks, with an EBITDA margin reported at -155.1%, a sign of operational inefficiencies. Meanwhile, their cost rationalization initiatives appear promising, emphasizing reduced debt levels and enhanced liquidity.

Market Reactions

During recent trading sessions, INM’s share price depicted high volatility with sharp declines reflective of investor caution. In particular, a drop in stock prices from $1.74 to $1.49 over subsequent days illustrates external market pressures.

Investors keenly observe the biotech firm’s strategic moves, particularly around innovative research breakthroughs—key drivers amplifying market confidence when successfully manifesting into profitable therapies.

The Road Ahead for InMed Pharmaceuticals

The road ahead is unsure. In a bid to navigate choppy waters, the biotechnology firm directs its capital towards reinforcing R&D and expanding partnerships across critical domains. As the biotech sector continues its evolutionary journey, InMed remains a crucial player, poised for resurgence in a challenging environment. Future growth may hinge on integrating strategic insights, leveraging core competencies, and sustaining trader trust.

In conclusion, InMed Pharmaceuticals faces myriad challenges coupled with opportunities for innovation within an unpredictable market landscape. As millionaire penny stock trader and teacher Tim Sykes says, “You must adapt to the market; the market will not adapt to you.” The company’s future moves will decisively impact trader confidence and sectoral momentum, marking this an intriguing chapter in its financial chronicles.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”